HighTower Advisors
IMVT icon

HighTower Advisors’s Immunovant IMVT Stock Holding History

HighTower Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000
Closed -$182 – 3893
2024
Q4 		$182 Hold
1,000
– – ﹤0.01% 3766
2024
Q3 		$2.17K Buy
+1,000
New +$29.5K ﹤0.01% 3629

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

HighTower Advisors's IMVT Position: Q3 2026 in Review

HighTower Advisors increased its Immunovant (IMVT) stake by 0.78% in Q3 2026, buying an estimated $17.2K and bringing the position to 56,541 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1822.

HighTower Advisors first reported a position in IMVT in Q4 2020 and has held it in 21 quarters since. The position peaked at $2.16M in Q2 2026. 160 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • HighTower Advisors held 56,541 shares of Immunovant worth $1.91M as of Q3 2026.
  • HighTower Advisors bought 437 Immunovant shares in Q3 2026, an estimated $17.2K.
  • Immunovant made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #1822 holding.
  • HighTower Advisors first reported a position in Immunovant in Q4 2020 and has held it in 21 quarters since.
  • HighTower Advisors's Immunovant position peaked at $2.16M in Q2 2026.
  • 160 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.